Alzheimer's Disease: Lecanemab in early Stage of the Disease?

被引：0
|
作者：
Simon, Annika
机构：
来源：
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2023年 / 148卷 / 10期
关键词：
D O I：
10.1055/a-2015-2042
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Die Akkumulation von aggregiertem Amyloid-beta (A beta) spielt in der Pathogenese von Morbus Alzheimer eine wichtige Rolle. Der humanisierte monoklonale IgG1-Antikorper Lecanemab bindet mit hoher Affinitat an A beta-losliche Protofibrillen und gilt als moglicher Wirkstoff zur Behandlung von Betroffenen im Fruhstadium. Van Dyck et al. haben Sicherheit und Wirksamkeit von Lecanemab gepruft und kommen in ihrer Phase-III-Studie zu einem gemischten Ergebnis.
引用
收藏
页码：593 / 594
页数：2
相关论文
共 50 条
  • [1] Lecanemab in Early Alzheimer's Disease
    van Dyck, Christopher H.
    Swanson, Chad J.
    Aisen, Paul
    Bateman, Randall J.
    Chen, Christopher
    Gee, Michelle
    Kanekiyo, Michio
    Li, David
    Reyderman, Larisa
    Cohen, Sharon
    Froelich, Lutz
    Katayama, Sadao
    Sabbagh, Marwan
    Vellas, Bruno
    Watson, David
    Dhadda, Shobha
    Irizarry, Michael
    Kramer, Lynn D.
    Iwatsubo, Takeshi
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (01): : 9 - 21
  • [2] Lecanemab in Early Alzheimer's Disease
    Zeng, Bing-Syuan H.
    Tseng, Ping-Tao
    Liang, Chih-Sung
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (17): : 1630 - 1632
  • [3] Lecanemab for Alzheimer's disease
    Walsh, Sebastian
    Merrick, Richard
    Richard, Edo
    Nurock, Shirley
    Brayne, Carol
    BMJ-BRITISH MEDICAL JOURNAL, 2022, 379
  • [4] Lecanemab for Alzheimer's disease
    Walsh, Sebastian
    Merrick, Richard
    Richard, Edo
    Nurock, Shirley
    Brayne, Carol
    BMJ-BRITISH MEDICAL JOURNAL, 2022, 379
  • [5] Treatment of Alzheimer's disease with lecanemab
    Peters, O.
    Nitschmann, S.
    INNERE MEDIZIN, 2023, 64 (04): : 406 - 408
  • [6] Lecanemab (Leqembi) for Alzheimer's Disease
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1669): : 17 - 18
  • [7] Cost-Effectiveness of Lecanemab (Leqembi) for Individuals With Early-Stage Alzheimer's Disease
    Nguyen, Hai V.
    Mital, Shweta
    Knopman, David
    Alexander, G. Caleb
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 381 - 382
  • [8] Lecanemab in the treatment of Alzheimer’s disease
    Peters O.
    Nitschmann S.
    Die Innere Medizin, 2023, 64 (4) : 406 - 408
  • [9] Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease
    Nguyen, Hai V.
    Mital, Shweta
    Knopman, David S.
    Alexander, G. Caleb
    NEUROLOGY, 2024, 102 (07) : e209218
  • [10] Lecanemab (Leqembi) Granted Full Approval for Early Alzheimer's Disease
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1683): : 129 - 130
12345